Injective (INJ), an innovative cryptocurrency token, is constantly making impressive strides within the financial and digital markets. Bitnomial, a renowned digital asset exchange platform, initiated the launch of Injective's futures in the United States, a move that has sparked speculation about ETF eligibility. This has led to an outpour of price prediction inquiries pertaining to the long-term viability of INJ as an investment.
As well,
Injective's blockchain technology is expanding. They announced support for native USDC and cross-chain transfers via Circle. Injective has also joined forces with Pineapple Financial to migrate its $10B mortgage portfolio onto the blockchain.
Injective has introduced a supply squeeze, which doubles its token deflation, generating investor interest. INJ's expected advances are making the news, predicting growth past the $50 mark by 2030. In addition, Canary has updated the Injective ETF with the SEC, engage massive speculations about a future rebound in the INJ price.
Notably, INJ ranges after the community-backed governance vote to slash the INJ token supply. Also, Injective's integration of native USDC transactions and its Real-Time USDC mainnet upgrade seems to boost its market price.
A temporary suspension from Binance for a network upgrade didn't appear to halt the INJ momentum. Furthermore, Canary Capital has also added Injective to its list of products through the filing for an INJ ETF that includes staking rewards.
Injective Coin News Analytics from Thu, 03 Mar 2022 03:34:04 GMT to Fri, 17 Apr 2026 01:22:44 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor -3
